IL280342A - Compositions of medically active particles with optimized surfaces by ultrafast freezing - Google Patents
Compositions of medically active particles with optimized surfaces by ultrafast freezingInfo
- Publication number
- IL280342A IL280342A IL280342A IL28034221A IL280342A IL 280342 A IL280342 A IL 280342A IL 280342 A IL280342 A IL 280342A IL 28034221 A IL28034221 A IL 28034221A IL 280342 A IL280342 A IL 280342A
- Authority
- IL
- Israel
- Prior art keywords
- ultra
- compositions
- therapeutically active
- active particles
- rapid freezing
- Prior art date
Links
- 230000008014 freezing Effects 0.000 title 1
- 238000007710 freezing Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702674P | 2018-07-24 | 2018-07-24 | |
| PCT/US2019/043202 WO2020023614A1 (en) | 2018-07-24 | 2019-07-24 | Compositions of surface-modified therapeutically active particles by ultra-rapid freezing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280342A true IL280342A (en) | 2021-03-25 |
Family
ID=69181152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280342A IL280342A (en) | 2018-07-24 | 2021-01-21 | Compositions of medically active particles with optimized surfaces by ultrafast freezing |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210338671A1 (https=) |
| EP (1) | EP3827260A4 (https=) |
| JP (2) | JP7611813B2 (https=) |
| KR (1) | KR20210038583A (https=) |
| CN (1) | CN112673257B (https=) |
| AU (1) | AU2019311086A1 (https=) |
| BR (1) | BR112021001290A2 (https=) |
| CA (1) | CA3106618A1 (https=) |
| EA (1) | EA202190331A1 (https=) |
| IL (1) | IL280342A (https=) |
| MX (1) | MX2021000796A (https=) |
| WO (1) | WO2020023614A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| CN113398079B (zh) * | 2020-03-16 | 2024-01-19 | 鲁南制药集团股份有限公司 | 一种注射用氟达拉滨冻干粉 |
| BR112023001929A2 (pt) | 2020-09-03 | 2023-03-14 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade |
| US20230301919A1 (en) * | 2020-09-03 | 2023-09-28 | Philip Morris Products S.A. | Freeze dried low hygroscopicity active powder compositions |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CN117241786A (zh) * | 2021-03-12 | 2023-12-15 | 德克萨斯大学系统董事会 | 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法 |
| US12015755B2 (en) | 2021-03-25 | 2024-06-18 | Korea Advanced Institute Of Science And Technology | Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof |
| CN113484469B (zh) * | 2021-06-30 | 2022-11-18 | 中国科学院青海盐湖研究所 | 水合盐体系相变储能材料纳米尺度相分离的原位表征方法 |
| CN116440084A (zh) * | 2022-01-07 | 2023-07-18 | 浙江萃泽医药科技有限公司 | 一种可吸入的药物粉末制剂及其制备方法 |
| AU2023366929A1 (en) | 2022-10-25 | 2025-05-08 | Veradermics, Incorporated | Compositions and methods of use for modified release minoxidil |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08310969A (ja) * | 1995-05-22 | 1996-11-26 | Lion Corp | 固形薬品組成物及びその製造方法 |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| CN1750811A (zh) * | 2001-10-19 | 2006-03-22 | 巴克斯特国际公司 | 在冷冻水基质中包括颗粒的稳定组合物 |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US9061027B2 (en) * | 2004-08-27 | 2015-06-23 | Board Of Regents, The University Of Texas System | Enhanced delivery of drug compositions to treat life threatening infections |
| WO2007011396A2 (en) * | 2004-10-29 | 2007-01-25 | President And Fellows Of Harvard College | Particles for treatment of pulmonary infection |
| US8361439B1 (en) * | 2005-01-04 | 2013-01-29 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| WO2007053923A2 (en) * | 2005-11-11 | 2007-05-18 | Biolab Sanus Farmacêutica Ltda. | Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same |
| WO2011046842A1 (en) * | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| US10973763B2 (en) * | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
| US9801855B2 (en) * | 2012-03-07 | 2017-10-31 | National Institute Of Pharmaceutical Education And Research (Niper) | Nanocrystalline solid dispersion compositions and process of preparation thereof |
| JP6940416B2 (ja) * | 2015-05-01 | 2021-09-29 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 多剤脆性マトリックス組成物 |
-
2019
- 2019-07-24 JP JP2021503813A patent/JP7611813B2/ja active Active
- 2019-07-24 AU AU2019311086A patent/AU2019311086A1/en active Pending
- 2019-07-24 CN CN201980055623.XA patent/CN112673257B/zh active Active
- 2019-07-24 CA CA3106618A patent/CA3106618A1/en active Pending
- 2019-07-24 US US17/262,313 patent/US20210338671A1/en active Pending
- 2019-07-24 EA EA202190331A patent/EA202190331A1/ru unknown
- 2019-07-24 WO PCT/US2019/043202 patent/WO2020023614A1/en not_active Ceased
- 2019-07-24 MX MX2021000796A patent/MX2021000796A/es unknown
- 2019-07-24 KR KR1020217005060A patent/KR20210038583A/ko not_active Ceased
- 2019-07-24 BR BR112021001290-7A patent/BR112021001290A2/pt unknown
- 2019-07-24 EP EP19840589.6A patent/EP3827260A4/en active Pending
-
2021
- 2021-01-21 IL IL280342A patent/IL280342A/en unknown
-
2024
- 2024-09-09 JP JP2024154560A patent/JP2024170583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202190331A1 (ru) | 2021-06-17 |
| JP2021530551A (ja) | 2021-11-11 |
| BR112021001290A2 (pt) | 2021-04-27 |
| CA3106618A1 (en) | 2020-01-30 |
| CN112673257A (zh) | 2021-04-16 |
| JP2024170583A (ja) | 2024-12-10 |
| MX2021000796A (es) | 2021-06-15 |
| US20210338671A1 (en) | 2021-11-04 |
| AU2019311086A1 (en) | 2021-02-04 |
| CN112673257B (zh) | 2025-02-25 |
| KR20210038583A (ko) | 2021-04-07 |
| WO2020023614A1 (en) | 2020-01-30 |
| EP3827260A1 (en) | 2021-06-02 |
| JP7611813B2 (ja) | 2025-01-10 |
| EP3827260A4 (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280342A (en) | Compositions of medically active particles with optimized surfaces by ultrafast freezing | |
| SG11202004734UA (en) | Vector for the production of aav particles | |
| EP3206497A4 (en) | Compositions and methods for the treatment of meibomian gland dysfunction | |
| GB201621508D0 (en) | Improvements relating to additive manufacture using charged particle beams | |
| EP3116492A4 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL247721A0 (en) | Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| IL279934A (en) | Crystalline forms of omecamtib from carbayl and its salts | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| GB201919131D0 (en) | Combining of spatial audio parameters | |
| GB201609017D0 (en) | Characterisation of particles | |
| GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL275843A (en) | Auxotropic strains of Staphylococcus bacteria | |
| GB2564937B (en) | Trajectory adjustment structure of gun | |
| IL290324A (en) | Preparations containing tropintide | |
| IL273850A (en) | Preparations and methods for the treatment of leprosy | |
| EP3955895C0 (en) | PRODUCTION OF SALIPRO PARTICLES | |
| ZA202105035B (en) | Therapeutic composition of intranasal lidocaine | |
| ZA201901099B (en) | Compositions for the treatment of pulmonary fibrosis | |
| GB201804427D0 (en) | Characterisation of amporphous content of complex formulations | |
| IL277773A (en) | Preparations and methods for the treatment of ischemia and cardiomyopathy | |
| IL263336B (en) | Compounds for the treatment of symphysiolysis | |
| PL4233872T3 (pl) | Mukoadhezyjne kompozycje farmaceutyczne kortykosteroidów | |
| HK40036545A (en) | Compositions and methods for treatment of fibrosis |